Recursion Pharmaceuticals, Inc.
RXRX
$4.64
$0.317.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.89% | -58.26% | 147.62% | 30.86% | 13.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.89% | -58.26% | 147.62% | 30.86% | 13.68% |
| Cost of Revenue | 92.39% | 40.02% | 7.16% | 29.00% | 33.15% |
| Gross Profit | -110.56% | -55.66% | 13.86% | -28.61% | -38.18% |
| SG&A Expenses | 74.00% | 144.25% | 29.31% | 12.52% | 44.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.15% | 69.74% | 13.04% | 23.97% | 36.25% |
| Operating Income | -98.64% | -83.66% | 1.20% | -23.04% | -40.24% |
| Income Before Tax | -119.90% | -84.32% | -2.86% | -27.81% | -41.06% |
| Income Tax Expenses | 79.72% | 100.17% | -- | -- | -- |
| Earnings from Continuing Operations | -121.60% | -92.38% | -3.04% | -27.13% | -39.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.60% | -92.38% | -3.04% | -27.13% | -39.87% |
| EBIT | -98.64% | -83.66% | 1.20% | -23.04% | -40.24% |
| EBITDA | -93.38% | -84.65% | 0.89% | -20.22% | -36.93% |
| EPS Basic | -29.86% | -27.77% | 21.84% | -5.72% | -13.55% |
| Normalized Basic EPS | -28.89% | -20.97% | 21.98% | -6.30% | -16.58% |
| EPS Diluted | -29.86% | -28.41% | 21.66% | -5.72% | -13.55% |
| Normalized Diluted EPS | -28.89% | -20.97% | 21.98% | -6.30% | -16.58% |
| Average Basic Shares Outstanding | 70.65% | 50.58% | 31.85% | 20.25% | 23.17% |
| Average Diluted Shares Outstanding | 70.65% | 50.58% | 31.85% | 20.25% | 23.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |